Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

March 28, 2022
Marks First Health Technology Assessment (HTA) Reimbursement in Europe and Initiation of Next Phase of the Company’s Growth Strategy Company Provides Progress Update on European and International Expansion Plans DUBLIN, Ireland and BRIDGEWATER, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Amarin
March 5, 2022

Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE‐IT Investigators. Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention: insights from REDUCE-IT PCI. J Am Heart Assoc. 2022; epub ahead of print.

https://www.ahajournals.org/doi/epub/10.1161/JAHA.121.022937

March 4, 2022

Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, King JB, Bellows BK, Tajeu GS, Derington CG, Johnson J, Andrade K, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P. Cost-effectiveness of icosapent ethyl for high-risk patients with hypertriglyceridemia despite statin treatment. JAMA Netw Open. 2022;5(2):e2148172.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789004

March 4, 2022

Singh N, Bhatt DL, Miller M, Steg G, Brinton EA, Jacobson TA, Jiao L, Tardif J-C, Mason RP, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Consistency of benefit of icosapent ethyl by background statin type in REDUCE-IT. J Am Coll Cardiol. 2022;79:220-222.

March 4, 2022

Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE-IT Investigators. Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT REVASC. Circulation. 2021;143:33-44.

March 3, 2022

Picard F, Bhatt DL, Ducrocq G, Ohman EM, Goto S, Eagle KA, Wilson PWF, Smith SC, Elbez Y, Steg PG. Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: an analysis of the REduction of Atherothrombosis for Continued Health (REACH) Registry. Int J Cardiol. 2021;340:96-104.